Crisaborole: a dermatologic perspective
Crisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US-FDA for the treatment of atopic dermatitis in children (> 3 months of age) and adults. More recently, its efficacy has been outlined in the treatment of many other dermatoses, in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia
2025-04-01
|
| Series: | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| Subjects: | |
| Online Access: | https://www.portuguesejournalofdermatology.com/frame_eng.php?id=241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Crisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US-FDA for the treatment of atopic dermatitis in children (> 3 months of age) and adults. More recently, its efficacy has been outlined in the treatment of many other dermatoses, including vitiligo, psoriasis, morphea, seborrheic dermatitis, stasis dermatitis, and vulvar leukoplakia, to name a few. While crisaborole represents a valuable non-steroidal alternative in dermatological therapy, the primary limitation is its high cost compared to other topical agents. Nevertheless, despite this limitation, its use in recalcitrant cases can be worth considering.
|
|---|---|
| ISSN: | 2182-2395 2182-2409 |